Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women

Postgraduate Medical Journal

Volumn 78, Issue 926, 2002, Pages 727-731

  Dogan, Erbil ^a   Posaci, C ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 1; CYTOKINE; ESTROGEN; OSTEOCALCIN;

BIOCHEMISTRY; BIOLOGICAL MONITORING; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE TISSUE; CROSS LINKING; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; MOLECULAR DYNAMICS; OSTEOLYSIS; PHYSIOLOGY; POSTMENOPAUSE; REVIEW;

BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MENOPAUSE; OSTEOCALCIN; PEPTIDES;

EID: 0036924560     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.78.926.727     Document Type: Review

References (28)

1. Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85:3069-76.
2. Pacifici R, Brown C, Puscheck E, et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A 1991;88:5134-8.
3. Posaci C, Altunyurt S, Islekel H, et al. Effects of HRT on serum levels of IGF-I in postmenopausal women. Maturitas 2001;40(1):69-74.
4. Pacifici R, Rifas L, McCracken R, et al. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc Natl Acad Sci U S A 1989;86:2398-402.
5. Kimble RB, Vannice JL, Bloedow DC, et al. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest 1994;93:1959-67.
6. Girasole G, Jilka RL, Passeri G, et al. 17 Beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 1992;89:883-91.
7. Poli V, Balena R, Fattori E, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994;13:1189-96.
8. Lindsay R. Prevention and treatment of osteoporosis. Lancet 1993;341:801-5.
9. Kanis JA. Are oestrogen deficiency and hormone replacement a distraction to the field of osteoporosis? Osteoporos Int 1998;8(suppl 1):51-6.
10. Delmas PD. HRT in the prevention and treatment of osteoporosis. J Epidemiol Biostat 1999;4:155-63.
11. Garnero P, Delmas PD. Biochemical markers of bone turnover: Clinical usefulness in osteoporosis. Ann Biol Clin 1999;57:137-48.
12. Delmas PD. Biochemical markers of bone turnover for the clinical investigation of osteoporosis. Osteoporos Int 1993;3(suppl 1):81-6.
13. Brincat M, Galea R, Baron YM, et al. Changes in bone collagen markers and in bone density in hormone treated and untreated postmenopausal women. Maturitas 1997;27(2):171-7.
14. Kraenzlin ME, Lau KH, Liang L, et al. Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J Clin Endocrinol Metab 1990;71:442-51.
15. Uebelhart D, Schlemmer A, Johansen JS, et al. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991;72:367-73.
16. Bjarnason NH, Christiansen C. The influence of thinness and smoking on bone loss and response to hormone replacement therapy in early postmenopausal women. J Clin Endocrinol Metab 2000;85:590-6.
17. Bjarnason NH, Christiansen C. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 2000;26:561-9.
18. Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999;84:2363-8.
19. Riis BJ, Hansen MA, Jensen AM, et al. Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture: A 15-year follow-up study. Bone 1996;19:9-12.
20. Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial. J Clin Endocrinol Metab 1999;84:3076-81.
21. Tiraş, MB, Noyan V, Yildiz A, et al. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: A prospective, randomized study. Hum Reprod 2000;15:2087-92.
22. Kyd PA, De Vooght K, Kerkhoff F, et al. Clinical usefulness of biochemical resorption markers in osteoporosis. Ann Clin Biochem 1999;36:483-91.
23. Marcus R, Holloway L, Wells B, et al. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res 1999;14:1583-95.
24. Rosen CJ, Chesnut CH 3rd, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997;82:1904-10.
25. Peris P, Alvarez L, Monegal A, et al. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy. Bone 1999;25:349-53.
26. Masahashi T, Negoro Y, Kuroki T, et al. Biochemical markers of bone turnover during hormone replacement therapy. Int J Gynaecol Obstet 1999;64:163-6.
27. Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: Prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996;81:2419-22.
28. Posaci C, Altunyurt S, Islekel H, et al. The values of urinary NTx in postmenopausal women undergoing hormone replacement therapy; the role of additional alendronate therapy. Maturitas 2002;42:281-6.